New drug offers ‘large step forward’ to treat advanced pancreatic cancer

A groundbreaking new pill is offering a beacon of hope for patients fighting advanced pancreatic cancer. Researchers revealed Sunday that the drug, known as daraxonrasib, has successfully helped patients live longer, marking a significant advancement in treating one of the world's most aggressive and lethal malignancies.

A Major Step Forward

Dr. Zev Wainberg of the University of California, Los Angeles, who played a leading role in the study, described the results as a "very large step forward." While the treatment is not a cure, it represents a monumental shift for a condition that has historically lacked effective long-term therapeutic options. By blocking a specific mutated protein that fuels tumor growth—a target that has proven elusive for decades—the drug addresses the root of more than 90% of pancreatic cancer cases.

Promising Clinical Results

The findings, presented at the American Society for Clinical Oncology meeting in Chicago and published in the New England Journal of Medicine, analyzed 500 patients whose metastatic cancer had stopped responding to standard chemotherapy. Those treated with daraxonrasib achieved a median survival of 13.2 months, compared to just 6.7 months for those receiving chemotherapy. Beyond extending life, participants reported a better quality of life and reduced pain as their tumors receded.

For many oncologists, the data is emotional. Dr. Rachna Shroff of the University of Arizona Cancer Center noted that the durability and meaningful benefits observed in patients were striking. Dr. Brian Wolpin of the Dana-Farber Cancer Institute, who presented the study, expressed his belief that the drug should become a "new standard of care" for metastatic cases, with future research slated to explore its potential to shrink tumors enough to make patients eligible for surgery.

Accessibility and Future Outlook

Recognizing the urgency, the U.S. Food and Drug Administration is expediting its review of daraxonrasib and has authorized an "expanded access" program. Eligible adult patients interested in the treatment can work with their physicians to request the drug from the manufacturer, Revolution Medicines.

Public interest has surged following reports, including an appearance on "60 Minutes" by former U.S. Sen. Ben Sasse, who shared his experience with the drug's pain-relieving effects. While the drug carries potential side effects, such as mouth sores and severe rashes, experts remain optimistic.

Pancreatic cancer remains a formidable challenge, with the American Cancer Society projecting approximately 67,000 new cases in the U.S. this year and a five-year survival rate of just 13%. However, the medical community sees this as a potential turning point. Dr. Andrew Coveler of the Fred Hutchinson Cancer Center noted that the drug functions differently than previous approaches, and researchers are already exploring additional KRAS-targeting therapies and immune-system-based vaccines to further improve patient outcomes.